Fundraising FoxAlexandria — 2022 Investments
10 investments dated 2022 · listed companies and verified rows first · show all
Aspen Neuroscience develops iPSC-derived autologous cell therapies for neurological diseases, with a lead product (ANPD001) in Phase 1/2a clinical trials for Parkinson's disease.
BiotechDeep TechDigital HealthMedical DevicesSan Diego, US
Andrés Bratt-Leal(Co-Founder and Senior Vice President, Research & Development)inANDRÉS BRATT-LEAL, Ph.D.(Co-Founder; Senior Vice President, Research & Development)Damien McDevitt(President and Chief Executive Officer)inDAMIEN MCDEVITT, Ph.D.(President and Chief Executive Officer)
Co-investorsARCH Venture PartnersLifeforce CapitalOrbiMedDomain AssociatesEDB InvestmentsSection 32+10 more
Discovering precision small molecule medicines that harness the power of covalency to transform the treatment of immune diseases.
BiotechCambridge, US
Andre Turenne(Executive Officer, Director)in
BoardJason Hafler(Director)inBruce Booth(Director)Daniel Becker(Director)
Co-investorsAccess BiotechnologyDigitalis VenturesSanofi VenturesAccess IndustriesAtlas Venture
A drug discovery company staffed by scientists and industry specialists focused on developing pharmaceutical candidates.
Biotech
Timur Yusufzai(Founder)inAsit Parikh(Chief Executive Officer)in
Co-investorsLifeSci Venture PartnersNextech InvestThird Rock VenturesCasdin CapitalCreacion VenturesGoldman Sachs+4 more
Ozette runs a vertically integrated, AI-enabled lab and platform that generates high-dimensional spectral cytometry data and analyzes it to produce reproducible biomarker endpoints for clinical trials.
AI & Machine LearningBiotechHealthtech
Greg Finak(Founder)inEvan Greene(Founder)inAli Ansary(Founder)inRaphael Gottardo(Founder)
Co-investorsAllen Institute for AI (AI2) IncubatorAlpha Ascent Ventures LlcM12 (Microsoft's Venture Fund)Cercano ManagementMadrona Venture GroupOCV Partners
Pheast Therapeutics develops immunotherapies targeting cancer, building on foundational research from Stanford's stem cell research institute.
BiotechHealthtechMedical DevicesRedwood City, US
Irv Weissman(Cofounder, Scientific Advisor, Board Director)Ravi Majeti(Cofounder, Scientific Advisor, Board Observer)Amira Barkal(Principal Founder, Scientific Advisor, Board Director)inRoy Maute(Cofounder & Chief Executive Officer)in
BoardJacob Vogelstein(Director)Steven Gillis(Director)in
Co-investorsARCH Venture PartnersCatalio Capital Management, LPCatalio Capital Management
Durham, US
Kris Wood(Director)inEoin McDonnell(Executive Officer, Director)in
Co-investorsKdT Ventures
Transforming the food system using seaweed, a highly sustainable protein source.
Albany, US
Beth Zotter(Executive Officer, Director)inAmanda Stiles(Director)in
Co-investorsClear Current CapitalCollaborative FundISVJuniperSustainable Food VenturesAgFunder+2 more
.jpeg){kind=logo}
Ventus AI is an enterprise automation platform offering AI agents ("AI teammates") that operate inside existing systems—desktop apps, web portals, and legacy software—without API integrations to automate complex business workflows, handling MFA, CAPTCHAs, and phone calls.
AI & Machine LearningEnterprise SoftwareHealthtechCasa Grande, US
Maran Vedamanikam(CEO and Manager)Peter Qian(Co-founder & CEO)Vincent Lu(Co-founder & CTO)
Co-investorsSamsung NextAndreessen HorowitzWndrCoBiotechnology Value FundCasdin CapitalFonds de solidarité FTQ+5 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.